Q2 2025 Cantargia AB Earnings Call Transcript
Key Points
- Cantargia AB (STU:7V3) secured a significant deal with Otsuka Pharmaceutical for CAN10, including a $33 million upfront payment and potential milestone payments up to $580 million.
- The U.S. FDA granted fast track designation to nadunolimab for treating pancreatic ductal adenocarcinoma, facilitating accelerated development and regulatory interactions.
- The company appointed Dr. Hilde Steineger as the new CEO, bringing extensive biotech and business development experience.
- Cantargia AB (STU:7V3) reported no safety concerns in their clinical trials, supporting further development of nadunolimab across multiple indications.
- The company maintains a robust pipeline with over 200 anti-IL1RAP antibodies, offering multiple development opportunities in both immunology and oncology.
- The TRIFOUR phase 2 study in triple-negative breast cancer did not show a difference in overall response rate between nadunolimab and chemotherapy alone.
- Cantargia AB (STU:7V3) experienced a 10% reduction in operating expenses, indicating potential financial constraints.
- The company faced increased administrative expenses due to activities related to the Otsuka transaction.
- There is uncertainty regarding the timing of milestone payments from the Otsuka deal, as specific details were not disclosed.
- Concerns were raised about potential market manipulation affecting the company's share price, though no insights were provided.
Welcome to the Cantargia Q2 Report 2025 presentation. (Operator Instructions)
Now I will hand the conference over to the speakers. CEO, Damian Marron; CFO, Patrik Renblad; and CBO, Ton Berkien, please go ahead.
Hello, everybody, and welcome to this presentation today of our 2Q and first half interim report 2025.
Moving straight on. We have our safe harbor statement. We are, of course, a listed company on Nasdaq Stockholm Exchange. And as has just been mentioned, you have 3 speakers here today, myself, Interim CEO; Ton Berkien, our Chief Business Officer; and Patrik Renblad, our Chief Financial Officer.
So moving to the events of the second quarter and the events since the end of that period as well. In the second quarter, we appointed Morten Lind Jensen as our Chief Medical Officer. We then moved on to select treatment-resistant atopic dermatitis as the second indication for our CAN10 phase 2 program, CAN10 being our anti-IL1RAP antibody for immune inflammatory
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
